IDIX – Actually, there is one new minor piece of news: the first paper on IDX375, IDIX’s non-nucleoside HCV polymerase inhibitor, will be presented at AASLD next month.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”